The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

The Swiss drugmaker, which holds European rights to Elevidys, suspended three trials while researchers investigate the death ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

For the presentation, please visit Scientific publications - Pipeline - Zealand Pharma. In March 2025, Zealand Pharma and Roche entered a collaboration and license agreement to co-develop and ...

Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to ...

Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity ...

Novo Nordisk’s phase III REDEFINE 2 study evaluating its next-gen subcutaneous obesity candidate, CagriSema, met its primary endpoint. CagriSema is a fixed-dose combination of a long-acting ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

ZURICH - Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the ...